受者HLA-DR纯合性与高质量供肾获取机会
该研究基于2015至2024年SRTR中262815例成人首次肾移植候选者,分析HLA-DR纯合性对死亡供肾移植(DDKT)获取的影响。结果显示HLA-DR纯合与总体DDKT获取略低相关(sHR 0.95),尤其与0错配DDKT获取显著降低相关(sHR 0.46),而与2错配DDKT获取增加相关(sHR 1.40),且此关联不受种族/民族影响。
要点
- HLA-DR纯合候选者获取高质量(0错配)DDKT的机会显著降低。
- HLA-DR纯合与总体DDKT获取略低相关,但2错配DDKT获取增加。
- 不同种族/民族中HLA-DR纯合均与0错配DDKT获取降低相关。
核心结论
- HLA-DR纯合与死亡供肾移植获取降低相关,尤其是高质量(0错配)供肾。
- 该关联在不同种族/民族中一致,提示移植分配应纳入HLA-DR纯合性以促进公平。
研究设计与样本
- 回顾性队列研究,使用SRTR数据,纳入262815例成人首次肾移植候选者(2015年1月1日至2024年5月31日)。
- 采用2021年OPTN等效表定义HLA-DR纯合性和错配,使用Fine-Gray竞争风险模型估计亚分布风险比(sHR)。
主要发现
- HLA-DR纯合与总体DDKT获取的sHR为0.95(95%CI 0.93-0.97)。
- HLA-DR纯合与0错配DDKT获取的sHR为0.46(95%CI 0.43-0.49),与1错配DDKT获取的sHR为0.83(95%CI 0.81-0.86)。
- HLA-DR纯合与2错配DDKT获取的sHR为1.40(95%CI 1.36-1.44)。
- 交互模型显示,所有种族/民族中HLA-DR纯合均与0错配DDKT获取降低相关。
临床怎么用
- 临床医生应关注HLA-DR纯合候选者获取高质量供肾的困难,在等待名单管理和咨询中予以考虑。
- 移植分配政策可考虑纳入HLA-DR纯合性以改善公平性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: A primary objective of transplantation is equitable access to quality deceased donor kidney transplantation (DDKT), which includes highly-matched human leukocyte antigen (HLA)-DR DDKT. Little research has been conducted on DDKT access among HLA-DR homozygous candidates, who have 2 serologically equivalent HLA-DR alleles and have low frequency in general populations. Our aim was to investigate DDKT access by HLA-DR mismatches across HLA-DR homozygosity and race/ethnicity. METHODS: Our Scientific Registry of Transplant Recipients (SRTR) sample included 262,815 adult, primary, kidney-only transplant candidates from January 1, 2015 to May 31, 2024. We used 2021 Organ Procurement and Transplantation Network (OPTN) equivalency tables to identify serologically equivalent HLA-DR antigens for defining HLA-DR homozygosity and mismatches. We conducted Fine and Gray's competing risk analysis to estimate subdistribution hazard ratios (sHRs) for receiving all DDKT and DDKT with 0, 1, and 2 HLA-DR mismatches by HLA-DR homozygosity alone and interacted with race/ethnicity. RESULTS: HLA-DR homozygosity was associated with a 0.95 sHR (95% confidence interval [CI]: 0.93-0.97) of receiving all DDKT, 0.46 sHR (95% CI: 0.43-0.49) of receiving DDKT with 0 HLA-DR mismatches, 0.83 sHR (95% CI: 0.81-0.86) of receiving DDKT with 1 HLA-DR mismatches, and conversely, 1.40 sHR (95% CI: 1.36-1.44) of receiving DDKT with 2 HLA-DR mismatches. Models interacting HLA-DR homozygosity and race/ethnicity showed that HLA-DR homozygosity was associated with a lower likelihood of receiving DDKT with 0 HLA-DR mismatches for all races/ethnicities. CONCLUSION: HLA-DR homozygosity was associated with lower access to DDKT, particularly highly-matched DDKT, irrespective of race/ethnicity. Prioritization for access to transplantation should incorporate HLA-DR homozygosity to promote equity.
引用
- Brosi DN, Lopez R, Arrigain S, et al. Recipient Human Leukocyte Antigen-DR Homozygosity and Access to Quality Kidneys. Kidney Int Rep. 2025. PMID: 41502812. doi:10.1016/j.ekir.2025.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。